BioAge Labs, Inc. (BIOA) analyst actions
Rating and price-target actions on BIOA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BIOA overview →
3 measured BIOA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Leqembi Iqlik® for initiation treatment launched in the US | Press release | -1.08% | -1.99% | |
| HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor | Press release | +0.31% | -1.44% | |
| Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status | Press release | +0.00% | +2.15% |
Keep exploring
More BIOA: earnings → · SEC filings → · BIOA overview →